Clinical Trial Update: Imaging Cannabinoid CB1 Receptors in Schizophrenia

View source ↗

Summary

The NIMH-sponsored study imaging cannabinoid CB1 receptors in schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Schizophrenia | Status: TERMINATED